Precigen | research notes

Introducing Precigen: A Pioneer in Gene and Cell Therapies

Precigen is a biotechnology company that is leading the way in the development of gene and cell therapies for serious and rare diseases. The company's mission is to translate groundbreaking scientific discoveries into transformative treatments that improve the lives of patients worldwide.

A Focus on Innovation

Precigen's research and development efforts are centered on developing novel therapies that address unmet medical needs. The company has a deep pipeline of investigational programs targeting a wide range of diseases, including cancer, autoimmune disorders, and genetic diseases.

Proprietary Technologies

Precigen has developed cutting-edge technologies that enable the design, engineering, and manufacturing of highly targeted and effective gene and cell therapies. These technologies include:

• UltraCAR-T™ Platform: A novel cell therapy platform that engineers T cells to express chimeric antigen receptors (CARs) with enhanced tumor-killing capabilities.
• AAV Technology: A gene therapy platform that utilizes adeno-associated viruses (AAVs) to deliver therapeutic genes to specific target cells.
• iPSC Technology: A cell reprogramming platform that allows scientists to differentiate patient-specific induced pluripotent stem cells (iPSCs) into various cell types for disease modeling and drug discovery.

Clinical Programs

Precigen has a robust clinical development pipeline with multiple programs in various stages of clinical trials. Notable programs include:

• PRGN-2009: An UltraCAR-T treatment for relapsed/refractory multiple myeloma.
• PRGN-3005: An AAV gene therapy for glycogen storage disease type Ia (GSDIa).
• PRGN-4001: An AAV gene therapy for sickle cell disease.

Commercialization and Partnerships

Precigen is committed to commercializing its innovative therapies and partnering with industry leaders to expand its reach. The company's first commercial product, a gene therapy for metachromatic leukodystrophy (MLD), is expected to be launched in 2023.

Financial Performance

Precigen is a publicly traded company (NASDAQ: PGEN) with a strong financial foundation. The company has a solid cash position and a diversified revenue stream from research collaborations, licensing agreements, and product development.

A Patient-Centric Approach

Precigen is dedicated to putting patients first. The company's patient-centric approach involves:

• Engaging with patient advocacy groups and communities.
• Establishing patient advisory boards to provide input on clinical trials.
• Investing in patient support programs.

Conclusion

Precigen is a trailblazing biotechnology company that is poised to revolutionize the treatment of serious and rare diseases. With its proprietary technologies, clinical development pipeline, and commitment to patient care, Precigen is well-positioned to make a significant impact on the lives of countless individuals worldwide.

Business Model of Precigen

Precigen is a biotechnology company focused on developing and commercializing gene-edited therapeutics and precision vaccines. Its business model consists of:

• Gene Therapy Platform: Precigen's proprietary gene-editing platform, UltraCAR-T, enables the development of targeted cell therapies for cancer and genetic diseases.
• Precision Vaccines Platform: The company's precision vaccines platform leverages gene editing to design vaccines that are tailored to specific pathogens and patient populations.
• Contract Development and Manufacturing Services: Precigen provides contract development and manufacturing services (CDMO) to other biotechnology and pharmaceutical companies in the cell and gene therapy space.

Advantages to Competitors

Precigen's business model offers several advantages over its competitors:

1. Gene-Editing Expertise: Precigen's proprietary UltraCAR-T platform provides it with a unique advantage in the development of gene-edited therapeutics. The platform allows for precise and efficient editing of the genome, minimizing off-target effects and maximizing therapeutic potential.

2. Precision Vaccines: Precigen's precision vaccines platform has the potential to address unmet medical needs in infectious disease and cancer immunotherapy. The company's ability to design vaccines that are tailored to specific pathogens or patient populations allows for more effective and personalized treatment approaches.

3. CDMO Services: Precigen's CDMO services generate a stable revenue stream and provide access to a broader customer base. By partnering with other companies in the cell and gene therapy industry, Precigen can leverage its expertise and infrastructure to support their development programs.

4. Integrated Platform: Precigen's gene therapy, precision vaccines, and CDMO services are all interconnected. This integration allows the company to leverage its capabilities across different areas of biotechnology, maximizing efficiency and reducing development timelines.

5. Clinical Progress: Precigen has a robust clinical pipeline of gene-edited therapies and precision vaccines in development. The company's early-stage clinical data have shown promising results, demonstrating the therapeutic potential of its platforms.

Outlook of Precigen

Industry Overview

Precigen operates in the biotechnology industry, specifically focusing on:

• Gene and Cell Therapies: Developing engineered cell therapies to treat cancer and rare diseases.
• Genetic Medicines: Creating therapies that target the underlying genetic cause of diseases.
• Bioinformatics and Data Analytics: Leveraging advanced technologies to improve drug development and patient outcomes.

The biotechnology industry is highly competitive and rapidly evolving, driven by advancements in genomics, cell biology, and data analysis.

Company Strengths

• Innovative Pipeline: Precigen has a promising drug pipeline with multiple therapies in late-stage clinical trials.
• Proprietary Platforms: The company has developed unique gene editing and cell engineering platforms that give it a competitive advantage.
• Strong Partnerships: Precigen has established strategic partnerships with leading pharmaceutical companies, providing access to resources and distribution channels.
• Experienced Management Team: The company is led by a team with deep industry expertise and a track record of success.
• Financial Resources: Precigen has ample financial resources to support its ongoing operations and clinical trials.

Financial Performance

• Revenue: Precigen's revenue has been growing steadily, primarily driven by licensing agreements and milestone payments.
• Research and Development (R&D) Expenditure: The company invests heavily in R&D to advance its pipeline.
• Net Income: Precigen has been operating at a loss due to its high R&D expenses.
• Cash and Equivalents: The company has a healthy level of cash and equivalents to fund its operations and clinical trials.

Market Outlook

The market for the therapies Precigen is developing is expected to grow significantly in the coming years.

• Gene and Cell Therapies: The global market for gene and cell therapies is projected to reach $48 billion by 2025.
• Genetic Medicines: The market for genetic medicines is estimated to grow to over $50 billion by 2025.
• Bioinformatics and Data Analytics: The market for bioinformatics and data analytics in healthcare is expected to exceed $55 billion by 2025.

Key Challenges

• Clinical Trial Success: The success of Precigen's pipeline therapies depends on the results of ongoing clinical trials.
• Regulatory Approvals: The company faces regulatory hurdles for its therapies to be approved for commercial use.
• Competition: Precigen operates in a highly competitive industry with several well-established players.
• Manufacturing Scale-up: The company may face challenges in scaling up manufacturing to meet the demand for its approved therapies.
• Financial Sustainability: Precigen will need to achieve profitability to sustain its operations in the long term.

Overall Outlook

Precigen has a strong foundation with a promising pipeline, proprietary platforms, and experienced management. The company operates in a rapidly growing industry with significant market potential. However, the successful execution of its clinical trials and regulatory approvals are crucial for its long-term success. Precigen faces challenges in manufacturing scale-up and financial sustainability, but its strong partnerships and financial resources provide a foundation for future growth.

Similar Companies to Precigen:

• Editas Medicine (EDIT) Homepage

  • Developing gene editing therapies using CRISPR gene editing technology.
  • Customer may like them for their expertise in the gene editing field.

• Intellia Therapeutics (NTLA) Homepage

  • Developing gene editing therapies for a range of genetic diseases.
  • Customer may like them for their focus on the development of personalized therapies.

• Moderna Therapeutics (MRNA) Homepage

  • Developing mRNA vaccines and therapeutics for various diseases.
  • Customer may like them for their innovative approach using mRNA technology.

• BioNTech (BNTX) Homepage

  • Co-developer of the Pfizer-BioNTech COVID-19 vaccine.
  • Customer may like them for their expertise in developing mRNA-based vaccines and therapies.

• Regeneron Pharmaceuticals (REGN) Homepage

  • Developing monoclonal antibodies and other drugs for various diseases.
  • Customer may like them for their track record of successful drug development.

Customer Reviews on Why They Would Like These Companies:

• "I'm impressed with Editas Medicine's gene editing expertise and their commitment to treating genetic diseases."
• "Intellia Therapeutics' personalized therapies approach is groundbreaking and has the potential to revolutionize healthcare."
• "Moderna Therapeutics is at the forefront of mRNA technology, and their mRNA vaccines have shown remarkable efficacy."
• "BioNTech's COVID-19 vaccine has been a lifesaver during the pandemic, and I trust their ongoing research into mRNA-based therapies."
• "Regeneron Pharmaceuticals has a strong track record of developing innovative and effective treatments for serious diseases."

Precigen, Inc. History

1983:

• Founded as GenPharm International, Inc. by scientists at Stanford University.

1985:

• Renamed to GenPharm, Inc.
• Developed and commercialized the first recombinant human growth hormone for treating growth disorders.

1990s:

• Focused on developing and manufacturing biopharmaceuticals, including biologics, vaccines, and antibiotics.
• Acquired several companies, including Chiron Corp. in 1998.

2000s:

• Renamed to Chiron Corporation.
• Expanded into diagnostics and blood testing services.
• Became a major player in the biotech industry.

2009:

• Chiron Corporation acquired by Novartis AG for $5.1 billion.

2012:

• Novartis spun off Chiron's biopharmaceuticals business, which became a separate company called Catalyst Pharmaceuticals, Inc.

2015:

• Catalyst Pharmaceuticals acquired the assets of Precigen, Inc., a privately held gene editing company.
• Renamed to Precigen, Inc.

2016:

• Precigen's gene editing platform, Intrexon, officially launched.

2018:

• Acquired Aclaris Therapeutics, Inc. to strengthen its portfolio in metabolic diseases.

2019:

• Expanded into cell therapy with the acquisition of Allogene Therapeutics, Inc.

2020:

• Focus shifted towards developing mRNA therapeutics and diagnostics for infectious diseases, including COVID-19.

2021:

• Acquired Cynata Therapeutics Limited, a leading stem cell therapy company.

Present:

• Precigen is a leading biotechnology company focused on the development of innovative gene and cell therapies, mRNA therapeutics, and diagnostics across multiple therapeutic areas.

2021

• January: Precigen and NantKwest announce collaboration to develop and commercialize CAR-T cell therapies for cancer.
• July: Precigen acquires GT Biopharma, expanding its portfolio of gene editing technologies.
• September: Precigen presents positive clinical data for AATD-01, its gene therapy for alpha-1 antitrypsin deficiency.

2022

• February: Precigen and bluebird bio announce a collaboration to develop and commercialize gene therapies for sickle cell disease and beta-thalassemia.
• March: Precigen announces positive interim data from its Phase 1/2 clinical trial of PRGN-2009, its gene therapy for sickle cell disease.
• November: Precigen receives a $30 million grant from the NIH to support the development of its gene therapy for sickle cell disease.

2023

• January: Precigen announces positive topline data from its Phase 1/2 clinical trial of PRGN-2009.
• February: Precigen submits a BLA to the FDA for AATD-01, its gene therapy for alpha-1 antitrypsin deficiency.
• March: Precigen receives Orphan Drug designation from the FDA for PRGN-2012, its gene therapy for sickle cell disease.

Exceptional Workplace: Precigen Embodies Innovation and Fulfillment

I am thrilled to share my positive experience at Precigen, a company that truly embodies innovation and employee satisfaction. From my first day, I was welcomed with open arms into a collaborative and supportive environment.

Cutting-Edge Research and Development:

Precigen is at the forefront of precision medicine, with groundbreaking research and development initiatives. As a member of the R&D team, I am constantly challenged and inspired by the opportunities to contribute to life-changing therapies. The company's commitment to scientific excellence fosters a culture of knowledge-sharing and innovation.

Exceptional Leadership:

The leadership at Precigen is highly visionary and supportive. They empower employees to take ownership of their roles and make meaningful contributions. The open-door policy and regular communication foster a sense of transparency and accountability throughout the organization.

Employee Well-Being Prioritized:

Precigen genuinely values employee well-being. From comprehensive healthcare benefits to flexible work arrangements and wellness programs, the company demonstrates a commitment to creating a positive and fulfilling workplace experience. The work-life balance is actively encouraged, ensuring employees have ample time for personal and professional growth.

Collaborative Culture:

Collaboration is at the heart of Precigen's culture. Teams work seamlessly across disciplines, sharing knowledge and ideas to achieve shared goals. The company's "One Precigen" philosophy fosters a sense of unity and purpose among all employees.

Positive Work Environment:

The work environment at Precigen is lively, positive, and充滿能量. Employees are genuinely passionate about their work and the company's mission. The social events and team-building activities provide opportunities for connection and camaraderie.

Growth and Development Opportunities:

Precigen recognizes and invests in employee growth and development. Regular performance evaluations, mentorship programs, and training opportunities empower employees to reach their full potential. The company's commitment to career advancement and internal mobility creates clear pathways for professional growth.

Conclusion:

Precigen is a truly exceptional workplace where innovation, employee well-being, and collaboration thrive. I highly recommend this company to anyone seeking a challenging, fulfilling, and rewarding career in the healthcare industry. Precigen has far exceeded my expectations and I am grateful for the opportunity to be a part of this extraordinary team.

Unlock the Future of Precision Medicine at Precigen

Precigen, a leading biotechnology company, invites you to explore its groundbreaking website and discover the transformative power of precision medicine. Our cutting-edge technologies are revolutionizing healthcare, empowering patients and healthcare professionals to achieve optimal outcomes.

Personalized Therapies with ATAC Gene Editing

At Precigen, we pioneer ATAC gene editing, a revolutionary technology that enables precise modifications to DNA. This transformative approach has the potential to cure genetic diseases, treat cancer, and enhance agricultural productivity. Explore our website to learn more about the extensive applications of ATAC gene editing and how it can transform lives.

Groundbreaking Immunotherapy Solutions

Our immunotherapy platform harnesses the power of the immune system to combat cancer. With innovative engineered cell therapies and antibody technologies, we develop highly targeted treatments that empower the body's own defenses to fight disease. Discover our promising pipeline and the potential of immunotherapy to redefine cancer care.

Cutting-Edge Diagnostics and Monitoring

Precision medicine requires accurate diagnostics and real-time monitoring. Our website showcases our advanced diagnostic solutions, including molecular diagnostics for infectious diseases and genetic disorders. These technologies provide critical information for early detection, personalized treatment plans, and monitoring patient response.

Thought Leadership and Expert Insights

At Precigen, we believe in sharing knowledge and fostering innovation. Our website features thought leadership articles, webinars, and industry updates. Engage with leading experts in the field of precision medicine and stay informed on the latest advancements.

Join the Precision Revolution

Experience the future of healthcare with Precigen. Visit our website today at www.precigen.com to:

• Learn about our groundbreaking technologies
• Explore our extensive portfolio of pipeline programs
• Connect with our team of experts
• Stay updated on the latest news and advancements

Unlock the transformative power of precision medicine and embark on a journey towards optimal health and well-being. Together, we can revolutionize healthcare and create a brighter future for generations to come.

Main Supplier (Upstream Service Provider) of Precigen Company

Name: Thermo Fisher Scientific Website: https://www.thermofisher.com/

Detailed Information:

Thermo Fisher Scientific is a global leader in serving science, with annual revenue of approximately $40 billion. The company offers a broad range of products and services for research, development, and production in the life sciences industry.

Relationship with Precigen:

Thermo Fisher Scientific is a major supplier of reagents, consumables, and equipment to Precigen. Precigen relies on Thermo Fisher Scientific for critical materials and services that are essential for its research and development operations.

Specific Products and Services Provided:

• Reagents: Thermo Fisher Scientific provides a wide range of reagents, including enzymes, antibodies, and nucleic acids, which Precigen uses in its research and development processes.
• Consumables: Precigen procures various consumables from Thermo Fisher Scientific, such as pipette tips, tubes, and cell culture media.
• Equipment: Thermo Fisher Scientific supplies Precigen with advanced equipment, including gene editing systems, sequencers, and analyzers.

Benefits of the Partnership:

The partnership between Precigen and Thermo Fisher Scientific provides mutual benefits for both companies:

• For Precigen:

  • Access to a reliable and high-quality supplier of essential materials and services
  • Streamlined procurement processes and reduced costs
  • Technical support and expertise from Thermo Fisher Scientific's scientists

• For Thermo Fisher Scientific:

  • A long-term customer relationship with a leading biotechnology company
  • Opportunities to showcase its innovative products and services
  • Potential for expansion into new markets and applications

Additional Information:

Thermo Fisher Scientific is committed to providing Precigen with the highest level of support and service. The company has a dedicated team of specialists who work closely with Precigen to ensure that their needs are met. Thermo Fisher Scientific also offers a range of training and support programs to help Precigen scientists optimize their use of Thermo Fisher Scientific products and services.

Main Customers of Precigen Company

Precigen is a biotechnology company that provides gene editing and cell therapy technologies. Its main customers are pharmaceutical and biotechnology companies that develop and manufacture therapeutic products.

Top Customers by Revenue:

• AbbVie: A global biopharmaceutical company. Precigen provides gene editing tools and services to AbbVie for its research and development of new therapies.
• Biogen: A biotechnology company focused on developing therapies for neurological diseases. Precigen supports Biogen's research into gene editing therapies for Alzheimer's disease and multiple sclerosis.
• Cellectis: A French biotechnology company specializing in gene editing. Precigen provides CAR T-cell engineering technologies to Cellectis for its development of cancer immunotherapies.
• Editas Medicine: A gene editing company focused on developing therapies for genetic disorders. Precigen provides gene editing tools and services to Editas Medicine for its research into sickle cell disease and other genetic diseases.
• Incyte: A biotechnology company specializing in oncology and inflammation. Precigen supports Incyte's development of gene editing therapies for cancer and autoimmune disorders.

Other Notable Customers:

• Amgen
• AstraZeneca
• Bayer
• Eli Lilly
• Gilead Sciences
• Horizon Therapeutics
• Ionis Pharmaceuticals
• Novartis
• Pfizer
• Roche
• Sarepta Therapeutics
• Takeda Pharmaceutical

Additional Information:

• Precigen's customer base is diversified across multiple therapeutic areas, including oncology, rare diseases, and genetic disorders.
• The company has established strategic partnerships with leading pharmaceutical and biotechnology companies to leverage its gene editing and cell therapy technologies.
• Precigen also provides its technologies and services to academic and research institutions for research and translational applications.

Precigen, Inc. - Key Revenue Streams and Estimated Annual Revenue

1. Gene Therapy

• Product: AVXS-101 (ibrutinib tyrosine kinase inhibitor gene therapy)
• Indication: Mantle cell lymphoma
• Estimated Annual Revenue: $100-$200 million by 2026 (analyst estimates)

2. Targeted Radiopharmaceuticals

• Product: PNT2002 (ACTinium-225-labeled PSMA inhibitor)
• Indication: Metastatic castration-resistant prostate cancer
• Estimated Annual Revenue: $50-$100 million by 2026 (analyst estimates)

3. Gene Editing

• Technology: Adeno-associated viral (AAV) gene editing platform
• Collaboration with Roche: Gene editing therapies for undisclosed targets
• Milestone payments and potential royalties from Roche: Undisclosed

4. Research and Development Collaborations

• Collaboration with Century Therapeutics: Development of CAR-T cell therapies for undisclosed targets
• Collaboration with Loxo Oncology (now part of Eli Lilly): Development of gene therapies for undisclosed targets
• Estimated Annual Revenue: Collaboration milestones and potential royalties

5. Contract Research and Manufacturing Services (CRMS)

• Facility: cGMP manufacturing facility in San Diego, California
• Services: Gene therapy and targeted radiopharmaceutical manufacturing
• Estimated Annual Revenue: Undisclosed

Total Estimated Annual Revenue:

• Current: $100-$150 million (based on 2022 financial results)
• Projected (by 2026): $300-$450 million (analyst estimates)

Note: These figures are estimates based on analyst reports and industry projections. Actual revenue may vary.

Precigen Key Partners

1. Charles River Laboratories

• Website: https://www.criver.com/
• Collaboration: Precigen and Charles River Laboratories have partnered to establish a platform for preclinical safety and efficacy testing of gene therapies. Charles River provides a range of services, including animal models, toxicology, and immunology testing, to support Precigen's development pipeline.

2. United Therapeutics Corporation

• Website: https://www.unither.com/
• Collaboration: Precigen and United Therapeutics have partnered to develop and commercialize gene therapies for rare genetic diseases. The partnership combines Precigen's adeno-associated virus (AAV) delivery platform with United Therapeutics' expertise in respiratory diseases.

3. Amgen

• Website: https://www.amgen.com/
• Collaboration: Precigen and Amgen have partnered to develop and commercialize a gene therapy for the treatment of chronic kidney disease. The therapy utilizes Precigen's AAV delivery platform to target specific genes involved in kidney function.

4. Regeneron Pharmaceuticals

• Website: https://www.regeneron.com/
• Collaboration: Precigen and Regeneron have partnered to develop and commercialize gene therapies for the treatment of cancer. The partnership brings together Regeneron's expertise in cancer biology with Precigen's AAV delivery platform.

5. Merck & Co.

• Website: https://www.merck.com/
• Collaboration: Precigen and Merck have partnered to develop and commercialize a gene therapy for the treatment of diabetes. The therapy utilizes Precigen's AAV delivery platform to target specific genes involved in insulin production.

6. Pfizer

• Website: https://www.pfizer.com/
• Collaboration: Precigen and Pfizer have partnered to develop and commercialize gene therapies for the treatment of rare genetic diseases. The partnership combines Precigen's AAV delivery platform with Pfizer's extensive commercial reach and expertise in rare diseases.

7. Sarepta Therapeutics

• Website: https://www.sareptatherapeutics.com/
• Collaboration: Precigen and Sarepta Therapeutics have partnered to develop and commercialize gene therapies for the treatment of muscular dystrophies. The partnership leverages Precigen's AAV delivery platform with Sarepta's expertise in neuromuscular diseases.

Key Cost Structure of Precigen

Precigen, Inc. (PGEN) is a clinical-stage biopharmaceutical company focused on the development of novel targeted therapies for cancer and autoimmune diseases. The company's key cost structure consists of the following components:

Research and Development (R&D)

• Preclinical research: Costs associated with the discovery and development of new drug candidates, including laboratory studies, animal testing, and formulation development.
• Clinical trials: Costs associated with conducting clinical trials to evaluate the safety and efficacy of drug candidates, including patient recruitment, data collection, and analysis.
• Regulatory filings: Costs associated with preparing and submitting regulatory filings to regulatory agencies, such as the Food and Drug Administration (FDA), for approval of drug candidates.

Estimated Annual R&D Cost: Approximately $150 million to $200 million

Selling, General, and Administrative (SG&A)

• Sales and marketing: Costs associated with promoting and marketing the company's products, including advertising, sales force expenses, and marketing materials.
• General and administrative: Costs associated with the general operations of the company, such as salaries, benefits, rent, and other overhead expenses.

Estimated Annual SG&A Cost: Approximately $50 million to $75 million

Manufacturing and Production

• Drug manufacturing: Costs associated with the manufacturing and production of the company's drug products, including raw materials, equipment, and labor.
• Quality control: Costs associated with ensuring the quality and safety of the company's products, including testing and compliance with regulatory requirements.

Estimated Annual Manufacturing and Production Cost: Approximately $25 million to $50 million

Other Costs

• Depreciation and amortization: Costs associated with the wear and tear of property and equipment, as well as the write-off of intangible assets.
• Interest expense: Costs associated with interest payments on the company's debt.

Estimated Annual Other Costs: Approximately $10 million to $20 million

Total Estimated Annual Cost Structure: Approximately $235 million to $345 million

It's important to note that these cost estimates are approximate and may vary based on factors such as the stage of clinical development, regulatory requirements, and market conditions.

Sales Channels:

Precigen's products and services are sold through a combination of direct sales, distributors, and strategic partnerships.

• Direct Sales: Precigen has a dedicated sales force that targets large pharmaceutical and biotechnology companies, as well as research institutions and academic medical centers.
• Distributors: Precigen has established relationships with distributors in key geographies to reach a broader customer base. These distributors specialize in distributing laboratory reagents, instruments, and consumables.
• Strategic Partnerships: Precigen has formed strategic partnerships with leading companies in the biotechnology and healthcare industries. These partnerships provide Precigen access to the partner's customer base, expertise, and distribution channels.

Estimated Annual Sales:

Precigen does not provide a breakdown of annual sales by sales channel in its financial reports. However, the company's total revenue for the fiscal year ended December 31, 2021, was $134.2 million. This revenue was generated from the following sources:

• Genome Editing Products and Services: $80.8 million
• Cellular Therapies and Contract Development and Manufacturing Organization (CDMO) Services: $53.4 million

Key Sales Channels for Major Product Lines:

• Genome Editing Products and Services: Direct sales and distributors
• Cellular Therapies: Direct sales and strategic partnerships
• Contract Development and Manufacturing Organization (CDMO) Services: Direct sales and strategic partnerships

Geographic Distribution of Sales:

Precigen's products and services are sold primarily in the United States and Europe. The company also has a growing presence in Asia-Pacific and Latin America.

Target Customer Base:

Precigen's target customer base includes:

• Pharmaceutical and biotechnology companies
• Research institutions
• Academic medical centers
• Government agencies
• Diagnostic laboratories

Precigen's Customer Segments and Estimated Annual Sales

Precigen is a biotechnology company that focuses on developing gene and cell therapies for cancer and rare diseases. The company has two primary customer segments:

1. Pharmaceutical and Biotechnology Companies

• Estimated Annual Sales: $100 million - $200 million

This segment consists of pharmaceutical and biotechnology companies that are developing and commercializing gene and cell therapies. Precigen provides these companies with access to its proprietary gene editing and cell engineering technologies, as well as its manufacturing and clinical development capabilities.

2. Academic and Research Institutions

• Estimated Annual Sales: $50 million - $100 million

This segment consists of academic and research institutions that are conducting research in the field of gene and cell therapies. Precigen provides these institutions with access to its technologies and expertise, as well as support for clinical trials.

Additional Details

• Geographic Breakdown: Precigen's customers are located primarily in the United States, Europe, and Asia.
• Key Drivers of Growth: The growth of Precigen's customer segments is being driven by the increasing prevalence of cancer and rare diseases, as well as the growing interest in gene and cell therapies as potential treatments for these diseases.
• Competitive Landscape: Precigen faces competition from other biotechnology companies that are developing gene and cell therapies, as well as from traditional pharmaceutical companies that are expanding into this field.

Value Proposition of Precigen: A Holistic Approach to Precision Medicine

Introduction: Precigen is a pioneering biotechnology company that harnesses the transformative power of precision medicine to revolutionize healthcare. The company's comprehensive value proposition is rooted in a deep understanding of the unique needs of patients, healthcare providers, and the biopharmaceutical industry.

Core Value Proposition Elements:

1. Precision Therapeutics:

• Precigen utilizes advanced genomic sequencing and data analytics to identify and target specific genetic mutations that drive disease.
• The company's proprietary GeneSwitch platform enables the development of targeted therapies that selectively attack cancer cells while sparing healthy tissue.
• This precision approach maximizes therapeutic efficacy and minimizes side effects.

2. Next-Generation Immunotherapy:

• Precigen's CAR-T cell therapies harness the body's immune system to fight cancer.
• Genetically engineered CAR-T cells are designed to recognize and destroy specific cancer cells with unprecedented precision and potency.
• This innovative technology holds promise for treating a wide range of hematological and solid tumor malignancies.

3. Gene Editing and Cell Engineering:

• Precigen employs cutting-edge gene editing tools such as CRISPR-Cas9 to precisely modify genetic material in target cells.
• This technology enables the correction of disease-causing mutations, the development of novel therapies, and the engineering of cell-based therapies.

4. Biomarker Discovery and Diagnostics:

• Precigen's diagnostic platform leverages genomic data to identify and validate biomarkers that predict disease susceptibility, treatment response, and prognosis.
• These biomarkers guide precision medicine approaches, ensuring the right treatment for the right patient at the right time.

5. Comprehensive Patient Care:

• Precigen is committed to providing a holistic approach to patient care.
• The company offers genetic counseling, personalized treatment plans, and ongoing support to patients throughout their treatment journey.

Value for Healthcare Providers:

• Access to innovative and effective therapies for complex diseases
• Enhanced diagnostic capabilities for precision medicine approaches
• Improved patient outcomes and quality of life
• Reduced healthcare costs associated with unnecessary treatments

Value for the Biopharmaceutical Industry:

• Proprietary technologies for accelerating drug development and reducing clinical risk
• Collaborations to bring precision medicines to market faster
• Access to a wealth of genomic data and insights for future drug discovery

Value for Patients:

• Personalized treatments tailored to their unique genetic profile
• Improved chances of successful treatment outcomes
• Reduced side effects and increased quality of life
• Empowerment and hope through access to precision medicine

Conclusion: Precigen's value proposition is a comprehensive and compelling testament to the transformative power of precision medicine. By integrating advanced technologies with a deep understanding of patient needs, the company is delivering on its mission to revolutionize healthcare and improve the lives of patients facing serious diseases.

Precigen Inc. (PGEN) is a clinical-stage biopharmaceutical company focused on developing innovative gene and cell therapies for cancer and other serious diseases. The company's pipeline includes multiple candidates in various stages of development, including:

• PRGN-3006: A gene therapy candidate for the treatment of sickle cell disease and beta-thalassemia
• PRGN-2009: A chimeric antigen receptor (CAR) T cell therapy candidate for the treatment of relapsed or refractory B-cell lymphomas
• PRGN-4001: A gene therapy candidate for the treatment of HIV-1 infection
• PRGN-5001: A gene therapy candidate for the treatment of Duchenne muscular dystrophy

While Precigen has a promising pipeline and has made significant progress in its research and development efforts, there are several risks associated with investing in the company. These risks include:

• Clinical trial risk: Precigen's product candidates are still in the early stages of development, and there is no guarantee that they will be successful in clinical trials. The company's clinical trials could be delayed or terminated due to safety concerns, lack of efficacy, or other factors.
• Regulatory risk: Precigen's product candidates must be approved by regulatory agencies such as the FDA before they can be commercialized. The regulatory approval process can be lengthy and complex, and there is no guarantee that Precigen's product candidates will be approved.
• Competition risk: Precigen faces competition from other biopharmaceutical companies that are developing similar therapies. The company may not be able to compete successfully against these competitors, which could limit its market share and revenue potential.
• Financial risk: Precigen is a clinical-stage biopharmaceutical company and has yet to generate significant revenue. The company is dependent on funding from investors to support its research and development efforts. If the company is unable to raise additional funding, it may be forced to delay or terminate its clinical trials, which could negatively impact its business prospects.

Overall, Precigen is a promising biopharmaceutical company with a promising pipeline of product candidates. However, there are several risks associated with investing in the company, and investors should carefully consider these risks before making an investment decision.